Paving the way towards a better tomorrow for people with Alzheimer’s disease
As we are still awaiting a blockbuster treatment for Alzheimer's disease, recent high-profile clinical trial failures have led to a feeling of ‘stakeholder fatigue’ and policy inertia in the Alzheimer’s disease arena. We helped our client, a leading pharmaceutical company, to find compelling new angles to refresh the policy debate and persuade stakeholders to re-engage.
We achieved this by launching a series of policy roundtables focussed on human rights, ethics and the value of treatment for Alzheimer's disease. This sparked discussion and renewed stakeholder engagement. Our subsequent policy report was endorsed by key influencers in the Alzheimer's space and its recommendations implemented by policymakers and patient groups alike.